Working with the global executive search firm Odgers Berndtson, the pan-Canadian Pharmaceutical Alliance (pCPA) is recruiting a chief executive officer as it continues its transition to a stand-alone organization. The new CEO is expected to be in place this spring. Read the full update.
pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
Update to the pCPA Strategic Revitalization: Next steps in the pCPA’s transition to a standalone organization
The pan-Canadian Pharmaceutical Alliance (pCPA) is an alliance of the provincial, territorial and federal governments that collaborates on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization
Member Jurisdictions
The pCPA member jurisdictions include public drug plans from:
